Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Todd M. Morgan et al.|European Urology|2018Cited by 93
Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular MarkersChris H. Bangma, Monique J. Roobol, Stacy Loeb et al.|European Urology|2013Cited by 58
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)Monique J. Roobol, Ellen C. Zwarthoff, Chris H. Bangma et al.|Urologic Oncology Seminars and Original Investigations|2010Cited by 44
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen Kalapara, Artitaya Lophatananon, Jan Verbeek et al.|European Urology Oncology|2019Cited by 37
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumByung Ha Chung, Weiyu Li, Daan Nieboer et al.|European Urology Open Science|2022Cited by 27